Clinical trials. Nail-biting time for trials of COX-2 drugs.
Couzin
Jennifer
J
D000544:Alzheimer Disease / Q000517:prevention & control*; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D018849:Controlled Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007417:Intestinal Polyps / Q000517:prevention & control; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000517:prevention & control*; D018579:Patient Selection; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013450:Sulfones
D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib